# Evaluation of Xueshuantong in Patients With AcutE IschemiC STroke

> **NCT04415164** · PHASE4 · UNKNOWN · sponsor: **Dongzhimen Hospital, Beijing** · enrollment: 480 (estimated)

## Conditions studied

- Acute Ischemic Stroke

## Interventions

- **DRUG:** Xueshuantong lyophilized powder
- **DRUG:** Placebo
- **OTHER:** Guidelines-based standard care

## Key facts

- **NCT ID:** NCT04415164
- **Lead sponsor:** Dongzhimen Hospital, Beijing
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-09-29
- **Primary completion:** 2022-10-31
- **Final completion:** 2023-05-31
- **Target enrollment:** 480 (ESTIMATED)
- **Last updated:** 2021-04-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04415164

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04415164, "Evaluation of Xueshuantong in Patients With AcutE IschemiC STroke". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04415164. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*